Novo Nordisk shares fell over 9% premarket after two late-stage trials showed Semaglutide, failed to slow Alzheimer disease progression despite biomarker improvements. The company is discontinuing the studies, which were launched based on real-world evidence and earlier analyses suggesting potential cognitive benefits.